^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CD19/NKG2DL CAR-T Therapeutic

i
Other names: CD19/NKG2DL CAR-T Therapeutic, NKG2D-based dual CAR T
Associations
Trials
Company:
Celyad Oncology
Drug class:
CD19-targeted CAR-T immunotherapy, NKG2D-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
over1year
NKG2D-Based Dual CAR T Cells to Overcome Antigen Escape and Improve AntiTumor Efficacy (IO-SUMMIT EUROPE 2023)
In vitro, T cells transduced with these constructs displayed cytotoxic activity, proliferated, and secreted cytokines in presence of WT and CD19 KO B-ALL cancer cells. Since NKG2DL are expressed in many cancer indications and absent from healthy tissues, use of NKG2DL-based dual CAR T cells is an attractive approach to improve anti-tumor efficacy in solid indications.
Clinical • CAR T-Cell Therapy
|
NKG2D (killer cell lectin like receptor K1)
|
CD19/NKG2DL CAR-T Therapeutic